|
Dr. Shorr has great stature in the biotechnology and pharmaceutical space. His expertise ranges from technological innovation, to strategic planning and implementation of research and business development, to the founding, financing and guiding of full commercialization of biotechnology ventures. Currently, Dr. Shorr is President of Cornerstone Pharmaceuticals, a company engaged in clinical development of a novel drug delivery technology for cancer. Concurrently, as a member of the Department of Biomedical Engineering at SUNY Stony Brook, he acts as Director of Business Development for the university's Center for Advanced Technology. Since 1999 he has also served as a trustee of Tissue Engineering Charities, Imperial College, London. In addition, he has continued financial interests and investments as a Principal in Altira Capital and Consulting LLC. Dr. Shorr was also Founder, VP Technology and Chief Scientific Officer for AT Biochem (later sold to FMC) and Associate Director, Department of Molecular Pharmacology at SmithKline and French from 1982 to 1988. He has published over 100 scientific/technical articles and has more than 100 inventions, issued or patent-pending worldwide, many of them commercialized. He holds a B.Sc. in Biology from the State University of Buffalo, a D.I.C. and a Ph.D. from the University of London.
| 